Diamedica Inc (DMCAF) 0.4823 $DMCAF
DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes
Marketwire - Thu Aug 07, 7:05AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced the publication of its manuscript entitled, "Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus," in PLOS ONE, an international, peer-reviewed, open access, scientific journal. The manuscript can be accessed at http://dx.plos.org/10.1371/journal.pone.0103981.
DMA.VN: 0.450 (+0.010)
DiaMedica to Present at InvestMNt Conference on August 6, 2014
Marketwire - Wed Jul 30, 7:03AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, announced today that the Company will present at the 2014 InvestMNt conference sponsored by CFA Society Minnesota.
DMA.VN: 0.450 (+0.010)
DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders
Marketwire - Fri Jul 25, 3:30PM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced that at its Annual General and Special Meeting (the "Meeting"
of shareholders held on July 24, 2014, Michael Giuffre, Rick Pauls, Richard Pilnik, Dawson Reimer and Thomas Wellner were re-elected as the Company's board of directors.
DMA.VN: 0.450 (+0.010)
DiaMedica Promotes Mark Robbins to Executive Vice President
Marketwire - Thu Jul 10, 7:31AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced the promotion of Mark Robbins, Ph.D., J.D., to Executive Vice President.
DMA.VN: 0.450 (+0.010)
DiaMedica Announces Stock Option Grant
Marketwire - Tue Jul 08, 4:10PM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced a grant of 150,000 stock options to Richard Pilnik, the Company's newly appointed Chairman of the Board. The options were awarded in accordance with the Stock Option Plan at an exercise price of CAD $0.69 and a term of 10 years. The options are subject to acceptance by the TSX Venture Exchange.
DMA.VN: 0.450 (+0.010)
DiaMedica Appoints Rich Pilnik as Chairman of the Board of Directors
Marketwire - Mon Jul 07, 7:31AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, announced today the appointment of Richard Pilnik as Chairman of the Company's Board of Directors.
LLY: 67.33 (-0.35), DMA.VN: 0.450 (+0.010)
Aon Benfield Exec: China Moving Towards Second Generation of Solvency Regime
Iris Lai - AMBest - Tue Feb 25, 11:08AM CST
China sees the need to move toward a new generation of solvency regime in light of global regulatory trends, the country's current market conditions and insurance growth over the past decade, according to Sifang Zhang, head of rating agency advisory at intermediary Aon Benfield.
DMA.VN: 0.450 (+0.010)
DiaMedica Inc. Announces Results of Annual General and Special Meeting
Marketwire - Fri Dec 20, 4:52PM CST
DiaMedica Inc. (TSX VENTURE: DMA), a biotechnology company focused on diabetes, is pleased to announce that at the Annual General and Special Meeting (the "Meeting" of shareholders of DiaMedica held on December 16, 2013, Michael Giuffre, Rick Pauls, Dawson Reimer, Richard Pilnik and Thomas Wellner were re-elected as the board of directors of DiaMedica.
DMA.VN: 0.450 (+0.010)
Influenza - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Influenza
M2 - Wed Sep 04, 11:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zj34n7/influenza) has announced the addition of the "Influenza - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Influenza - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Influenza, complete with latest updates, and special features on late-stage and discontinued projects. Influenza - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Influenza. - A review of the Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Influenza pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - 4SC AG - AIMM Therapeutics B.V. - Amarillo Biosciences, Inc. - BioAlliance Pharma SA - Biotron Limited - CEL-SCI Corporation - DiaMedica Inc. - Evolva SA - Functional Genetics, Inc. - Generex Biotechnology Corporation - GlaxoSmithKline plc - Green Cross Corporation - Hawaii Biotech, Inc. - Inovio Biomedical Corporation - Johnson & Johnson - Novartis AG - Novavax, Inc. - Okairos - Panacea Biotec Limited - PaxVax - PepTcell Limited - Quantum Pharmaceuticals - Romark Laboratories, L.C. - Sanofi-Aventis - Trellis Bioscience, Inc. - UMN Pharma Inc. - Vivaldi Biosciences Inc. - Wittycell S.A.S. - XOMA Ltd. - Zosano Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/zj34n7/influenza About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
JNJ: 108.16 (-0.91), INO: 11.00 (-0.01), CVM: 0.65 (+0.04), NVAX: 5.28 (+0.09), GSK: 45.74 (+0.08), NVS: 93.95 (-0.43)
DiaMedica Issues Stock Option Grant
Marketwire - Wed Jun 26, 5:23AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), announces that the Board of Directors has granted options to purchase 525,000 common shares of the Corporation to certain of its officers and directors. The options were issued at an exercise price of $1.07 per share for a ten-year term.
DMA.VN: 0.450 (+0.010)
Pancreatic Cancer - Pipeline Review, H1 2013 Gives a Snapshot of the Global Therapeutic Scenario for Pancreatic Cancer
M2 - Wed Jun 05, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g6cvrj/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Pancreatic Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Cancer. Pancreatic Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A review of the Pancreatic Cancer products under dev
INCY: 69.54 (-1.67), LLY: 67.33 (-0.35), BMY: 57.95 (+0.15), GSK: 45.74 (+0.08), OMER: 18.98 (-0.59), GILD: 102.06 (-2.14), AZN: 72.85 (-1.68), NVS: 93.95 (-0.43)
DiaMedica Announces Initiation of Phase I/II Clinical Trial for Potential First-in-Class Treatment of Type 2 Diabetes
Marketwire Canada - Wed May 01, 7:07AM CDT
DiaMedica Inc. (TSX VENTURE
MA) announces the commencement of its Phase I/II trial with first in human dosing of DM-199; a recombinant protein therapy for the treatment of diabetes and associated complications. As described in the April 8th 2013 press release, the study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of DM-199 in 36 healthy volunteers and in 40 Type 2 diabetic patients.
DMA.VN: 0.450 (+0.010)
DiaMedica Inc. Announces Public Offering
Marketwire Canada - Mon Feb 25, 9:05PM CST
DiaMedica Inc. (TSX VENTURE MA), announced today that it has filed a preliminary short form prospectus in connection with the public offering (the "Offering" of units of DiaMedica (the "Units" . The Offering is being placed on a commercially reasonable efforts agency basis by Sora Group Wealth Advisors Inc.
DMA.VN: 0.450 (+0.010)
DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes
Marketwire - Thu Aug 07, 7:05AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced the publication of its manuscript entitled, "Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus," in PLOS ONE, an international, peer-reviewed, open access, scientific journal. The manuscript can be accessed at http://dx.plos.org/10.1371/journal.pone.0103981.
DMA.VN: 0.450 (+0.010)
DiaMedica to Present at InvestMNt Conference on August 6, 2014
Marketwire - Wed Jul 30, 7:03AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, announced today that the Company will present at the 2014 InvestMNt conference sponsored by CFA Society Minnesota.
DMA.VN: 0.450 (+0.010)
DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders
Marketwire - Fri Jul 25, 3:30PM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced that at its Annual General and Special Meeting (the "Meeting"
of shareholders held on July 24, 2014, Michael Giuffre, Rick Pauls, Richard Pilnik, Dawson Reimer and Thomas Wellner were re-elected as the Company's board of directors. DMA.VN: 0.450 (+0.010)
DiaMedica Promotes Mark Robbins to Executive Vice President
Marketwire - Thu Jul 10, 7:31AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced the promotion of Mark Robbins, Ph.D., J.D., to Executive Vice President.
DMA.VN: 0.450 (+0.010)
DiaMedica Announces Stock Option Grant
Marketwire - Tue Jul 08, 4:10PM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced a grant of 150,000 stock options to Richard Pilnik, the Company's newly appointed Chairman of the Board. The options were awarded in accordance with the Stock Option Plan at an exercise price of CAD $0.69 and a term of 10 years. The options are subject to acceptance by the TSX Venture Exchange.
DMA.VN: 0.450 (+0.010)
DiaMedica Appoints Rich Pilnik as Chairman of the Board of Directors
Marketwire - Mon Jul 07, 7:31AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, announced today the appointment of Richard Pilnik as Chairman of the Company's Board of Directors.
LLY: 67.33 (-0.35), DMA.VN: 0.450 (+0.010)
Aon Benfield Exec: China Moving Towards Second Generation of Solvency Regime
Iris Lai - AMBest - Tue Feb 25, 11:08AM CST
China sees the need to move toward a new generation of solvency regime in light of global regulatory trends, the country's current market conditions and insurance growth over the past decade, according to Sifang Zhang, head of rating agency advisory at intermediary Aon Benfield.
DMA.VN: 0.450 (+0.010)
DiaMedica Inc. Announces Results of Annual General and Special Meeting
Marketwire - Fri Dec 20, 4:52PM CST
DiaMedica Inc. (TSX VENTURE: DMA), a biotechnology company focused on diabetes, is pleased to announce that at the Annual General and Special Meeting (the "Meeting"
of shareholders of DiaMedica held on December 16, 2013, Michael Giuffre, Rick Pauls, Dawson Reimer, Richard Pilnik and Thomas Wellner were re-elected as the board of directors of DiaMedica. DMA.VN: 0.450 (+0.010)
Influenza - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Influenza
M2 - Wed Sep 04, 11:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zj34n7/influenza) has announced the addition of the "Influenza - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Influenza - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Influenza, complete with latest updates, and special features on late-stage and discontinued projects. Influenza - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Influenza. - A review of the Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Influenza pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - 4SC AG - AIMM Therapeutics B.V. - Amarillo Biosciences, Inc. - BioAlliance Pharma SA - Biotron Limited - CEL-SCI Corporation - DiaMedica Inc. - Evolva SA - Functional Genetics, Inc. - Generex Biotechnology Corporation - GlaxoSmithKline plc - Green Cross Corporation - Hawaii Biotech, Inc. - Inovio Biomedical Corporation - Johnson & Johnson - Novartis AG - Novavax, Inc. - Okairos - Panacea Biotec Limited - PaxVax - PepTcell Limited - Quantum Pharmaceuticals - Romark Laboratories, L.C. - Sanofi-Aventis - Trellis Bioscience, Inc. - UMN Pharma Inc. - Vivaldi Biosciences Inc. - Wittycell S.A.S. - XOMA Ltd. - Zosano Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/zj34n7/influenza About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
JNJ: 108.16 (-0.91), INO: 11.00 (-0.01), CVM: 0.65 (+0.04), NVAX: 5.28 (+0.09), GSK: 45.74 (+0.08), NVS: 93.95 (-0.43)
DiaMedica Issues Stock Option Grant
Marketwire - Wed Jun 26, 5:23AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), announces that the Board of Directors has granted options to purchase 525,000 common shares of the Corporation to certain of its officers and directors. The options were issued at an exercise price of $1.07 per share for a ten-year term.
DMA.VN: 0.450 (+0.010)
Pancreatic Cancer - Pipeline Review, H1 2013 Gives a Snapshot of the Global Therapeutic Scenario for Pancreatic Cancer
M2 - Wed Jun 05, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g6cvrj/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Pancreatic Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Cancer. Pancreatic Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A review of the Pancreatic Cancer products under dev
INCY: 69.54 (-1.67), LLY: 67.33 (-0.35), BMY: 57.95 (+0.15), GSK: 45.74 (+0.08), OMER: 18.98 (-0.59), GILD: 102.06 (-2.14), AZN: 72.85 (-1.68), NVS: 93.95 (-0.43)
DiaMedica Announces Initiation of Phase I/II Clinical Trial for Potential First-in-Class Treatment of Type 2 Diabetes
Marketwire Canada - Wed May 01, 7:07AM CDT
DiaMedica Inc. (TSX VENTURE
MA) announces the commencement of its Phase I/II trial with first in human dosing of DM-199; a recombinant protein therapy for the treatment of diabetes and associated complications. As described in the April 8th 2013 press release, the study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of DM-199 in 36 healthy volunteers and in 40 Type 2 diabetic patients. DMA.VN: 0.450 (+0.010)
DiaMedica Inc. Announces Public Offering
Marketwire Canada - Mon Feb 25, 9:05PM CST
DiaMedica Inc. (TSX VENTURE
MA), announced today that it has filed a preliminary short form prospectus in connection with the public offering (the "Offering" of units of DiaMedica (the "Units" . The Offering is being placed on a commercially reasonable efforts agency basis by Sora Group Wealth Advisors Inc. DMA.VN: 0.450 (+0.010)
